On Tuesday, Pfizer and BioNTech announced they’re seeking authorization from the Food and Drug Administration for the first two doses of a planned three-dose Covid-19 vaccine regimen for children under 5 — the last age bracket remaining witout a Covid-19 vaccine. The agency said that it would convene its independent panel of vaccine experts on Feb. 15 to consider the data. While many welcomed the new development, some pediatricians raised concerns that the companies were moving too quickly. Lauren Gardner reports.

Learn more about your ad choices. Visit megaphone.fm/adchoices